Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone Carotid Plaque Study
NCT00123227Phase 3Unknown
- Sponsor
- Royal Brompton and Harefield hospitals
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerosis comparing Rosiglitazone with Placebo (2 arms). Primary endpoint: Plaque volume change over 12 months. Status: unknown.
02
Drugs
rosiglitazone
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT00123227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123227.